UA92146C2 - Стабилизированная жидкая композиция, которая содержит интерферон - Google Patents

Стабилизированная жидкая композиция, которая содержит интерферон

Info

Publication number
UA92146C2
UA92146C2 UAA200612406A UAA200612406A UA92146C2 UA 92146 C2 UA92146 C2 UA 92146C2 UA A200612406 A UAA200612406 A UA A200612406A UA A200612406 A UAA200612406 A UA A200612406A UA 92146 C2 UA92146 C2 UA 92146C2
Authority
UA
Ukraine
Prior art keywords
concentration
liquid formulations
stabilized interferon
interferon liquid
poloxamer
Prior art date
Application number
UAA200612406A
Other languages
English (en)
Ukrainian (uk)
Inventor
Фабрицио Самаритани
Рио Алессандра Дель
Original Assignee
Эйрэс Трейдинг С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйрэс Трейдинг С.А. filed Critical Эйрэс Трейдинг С.А.
Publication of UA92146C2 publication Critical patent/UA92146C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
UAA200612406A 2004-06-01 2005-05-27 Стабилизированная жидкая композиция, которая содержит интерферон UA92146C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04076626 2004-06-01

Publications (1)

Publication Number Publication Date
UA92146C2 true UA92146C2 (ru) 2010-10-11

Family

ID=34928261

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200612406A UA92146C2 (ru) 2004-06-01 2005-05-27 Стабилизированная жидкая композиция, которая содержит интерферон

Country Status (14)

Country Link
US (1) US7731948B2 (ru)
EP (1) EP1750751B1 (ru)
JP (1) JP4988562B2 (ru)
CN (1) CN1993139B (ru)
AU (1) AU2005249233B2 (ru)
BR (1) BRPI0510526A (ru)
CA (1) CA2567310A1 (ru)
EA (1) EA010979B1 (ru)
ES (1) ES2418833T3 (ru)
IL (1) IL179620A (ru)
MX (1) MXPA06014078A (ru)
NO (1) NO20065860L (ru)
UA (1) UA92146C2 (ru)
WO (1) WO2005117949A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20110699T1 (hr) * 2003-12-11 2011-10-31 Ares Trading S.A. Stabilne tekuće formulacije interferona
US7879320B2 (en) 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
CA2571800A1 (en) * 2005-12-23 2007-06-23 Canadian Blood Services Nitrophenyls and related compounds and thimerosal for the inhibition of immune related cell or tissue destruction
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
WO2008066322A1 (en) * 2006-11-28 2008-06-05 Daewoong Co., Ltd. A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta
AU2008269086B2 (en) 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
RS52417B (sr) * 2007-12-20 2013-02-28 Merck Serono S.A. Formulacije peg-interferona-beta
SG184355A1 (en) * 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta
CA2846786C (en) 2011-03-15 2022-05-17 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
RU2527701C1 (ru) * 2013-05-24 2014-09-10 Федеральное государственное бюджетное учреждение "Научный центр реконструктивной и восстановительной хирургии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НЦРВХ" СО РАМН) Способ приготовления средства, обладающего свойством стимуляции регенерации хрящевой, костной, мышечной тканей и способ стимуляции регенерации хрящевой, костной, мышечной тканей с использованием приготовленного средства
ES2736503T3 (es) * 2014-04-04 2020-01-02 Ares Trading Sa Nuevos análogos de la proteína IFN beta
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN114053397B (zh) * 2022-01-17 2022-12-20 北京三元基因药业股份有限公司 一种稳定的干扰素多剂量注射液及其制备方法
CN120549858A (zh) * 2025-07-31 2025-08-29 长春生物制品研究所有限责任公司 重组人干扰素α1b溶液及其制备方法与应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4469228A (en) * 1983-05-31 1984-09-04 Schering Corporation Interferon kit
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IT1244511B (it) 1991-04-15 1994-07-15 Isi Ist Sierovaccinogeno Ital Idrogeli a base di policarbossilati sintetici e proteine per il rilascio controllato di farmaci e procedimento per la loro preparazione.
KR960009385B1 (en) * 1993-11-24 1996-07-18 Samsung Bp Chemicals Co Ltd Apparatus and method for wastewater treatment by activated sludge process type
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5858001A (en) 1995-12-11 1999-01-12 Elan Medical Technologies Limited Cartridge-based drug delivery device
ATE318580T1 (de) * 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
DK1017413T4 (da) 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
CA2311681A1 (en) * 1997-12-08 1999-06-17 Genentech, Inc. Human interferon-epsilon: a type i interferon
DE69936409T2 (de) 1998-04-28 2008-04-17 Laboratoires Serono S.A., Coinsins Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
CZ305123B6 (cs) * 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6586785B2 (en) 2000-06-29 2003-07-01 California Institute Of Technology Aerosol silicon nanoparticles for use in semiconductor device fabrication
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
ES2290095T3 (es) 2000-12-27 2008-02-16 Ares Trading S.A. Microparticulas lipidicas por micronizacion criogenica.
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
NZ535008A (en) 2002-02-08 2005-09-30 Alkermes Inc Polymer-based compositions for sustained release
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
US7879320B2 (en) 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations

Also Published As

Publication number Publication date
HK1102563A1 (en) 2007-11-30
IL179620A0 (en) 2007-05-15
EA200602257A1 (ru) 2007-04-27
US7731948B2 (en) 2010-06-08
CN1993139A (zh) 2007-07-04
EP1750751A1 (en) 2007-02-14
EA010979B1 (ru) 2008-12-30
IL179620A (en) 2013-04-30
CN1993139B (zh) 2011-02-16
WO2005117949A1 (en) 2005-12-15
MXPA06014078A (es) 2007-02-15
BRPI0510526A (pt) 2007-10-30
JP2008500996A (ja) 2008-01-17
US20070292391A1 (en) 2007-12-20
NO20065860L (no) 2006-12-19
CA2567310A1 (en) 2005-12-15
JP4988562B2 (ja) 2012-08-01
ES2418833T3 (es) 2013-08-16
AU2005249233B2 (en) 2010-10-07
EP1750751B1 (en) 2013-04-10
AU2005249233A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
NZ603900A (en) Subcutaneous anti-her2 antibody formulation
AR098830A2 (es) Suspensiones acuosas estabilizadas para administración parenteral
AR018526A1 (es) COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED
MY162623A (en) Immunoglobulin formulation and method of preparation thereof
MXPA05012191A (es) Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos.
NZ613809A (en) Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
UY27320A1 (es) Nuevas composiciones farmacéuticas
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NZ594055A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
NZ595526A (en) Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
NZ593190A (en) Factor viii formulations
WO2002100344A3 (en) Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
TW200735897A (en) HFSH aqueous formulation
MY206282A (en) Protein solution formulation containing high concentration of an anti-vegf antibody
PL357132A1 (en) Stable, nasally, orally or sublingually applicable pharmaceutical preparation
TR200003688T1 (tr) Glutation'un absorbsıyonu'nun arttırılması ve etkilerinin güçlendirilmesi için kompozisyon
PT1589949E (pt) Composições liofilizadas estabilizadas compreendendo inibidor da coagulação por factores tecidulares ou variante de inibidor da coagulação por factores tecidulares
WO2001047913A3 (de) Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung
WO2007056264A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2002042414A3 (en) Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2004112838A3 (en) Codrugs of diclofenac
EA200602257A1 (ru) Стабилизированные жидкие препаративные формы интерферона
WO2006040112A3 (en) Taste-masking pharmaceutical compositions